Pulmonary Edema Market Size To Grow At A CAGR Of 7.8 % In The Forecast Period Of 2025-2032
Pulmonary Edema Market
Market Estimation & Definition
Pulmonary edema is a serious medical condition in which excess fluid accumulates in the lungs, impairing gas exchange and causing difficulty in breathing. It can be cardiogenic, due to heart failure, or non-cardiogenic, arising from lung injury, infection, trauma, or toxic exposure. According to Stellar Market Research, the global pulmonary edema market was valued at approximately USD 6.6 billion in 2024 and is forecast to grow at a CAGR of 7.8% from 2025 to 2032, reaching nearly USD 12.04 billion by 2032.
Request Free Sample Report:
https://www.stellarmr.com/report/req_sample/pulmonary-edema-market/2673
Market Growth Drivers & Opportunity
Key factors driving the growth of the pulmonary edema market include:
Rising Cardiovascular Disease (CVD) Prevalence: Heart disease is one of the primary causes of cardiogenic pulmonary edema. With increasing global rates of heart failure, coronary artery disease and hypertension, more patients are at risk.
Growing Incidence of Trauma and Accidents: Road accidents and chest injuries contribute significantly to non-cardiogenic pulmonary edema, creating acute treatment demand.
Aging Population: As the population ages, comorbid conditions (heart disease, kidney issues) that predispose individuals to pulmonary edema become more common.
Innovative Therapies: Advances in drugs — for example, combinations such as sacubitril/valsartan — and novel therapeutics (e.g., synthetic peptides) are improving outcomes.
Improved Diagnostics: Enhanced diagnostic tools, including imaging (CT, ultrasound) and deep-learning–assisted lung evaluation, are helping earlier detection and management.
These drivers create strong opportunities for pharmaceutical companies, medical technology firms, and healthcare providers to invest in treatments, diagnostics, and long-term care solutions for pulmonary edema.
What Lies Ahead: Emerging Trends Shaping the Future
Several emerging trends are expected to shape the pulmonary edema market in the coming years:
Precision Therapies & Peptide-Based Drugs: Newer molecules like synthetic peptides (such as solnatide) are being developed to more precisely manage fluid accumulation in the lungs.
Repurposing Existing Drugs: Drugs currently used for heart failure (e.g., sacubitril/valsartan) are being more widely adopted or optimized to prevent or manage pulmonary edema.
Growth in Diagnostic Imaging: Lung ultrasound combined with AI and deep learning is emerging as a powerful tool in assessing and monitoring pulmonary edema severity.
Expansion of Healthcare Infrastructure: In emerging markets, expanding hospital capacity, better access to intensive care, and growing awareness will drive demand for pulmonary edema treatment.
Regenerative and Device-Based Support: As treatment paradigms evolve, there may be more integration of device-based support (ventilation) with pharmacological therapy.
Risks remain, including regulatory hurdles for new drugs, high costs for R&D, and inequalities in access to advanced diagnostics.
Segmentation Analysis
The report breaks down the pulmonary edema market as follows:
By Disease Type:
Cardiogenic Pulmonary Edema (driven primarily by heart failure)
Non-Cardiogenic Pulmonary Edema (caused by lung injury, infection, trauma, or altitude)
By Diagnosis Type:
Imaging Techniques (chest X-ray, CT scans, lung ultrasound)
Laboratory Tests (blood gas analysis, biomarkers)
By Treatment Type:
Oxygen Therapy (supplemental oxygen)
Medications (diuretics, vasodilators, heart failure drugs)
Surgical Interventions (e.g., valve repair, bypass grafting)
By End User:
Hospitals & Clinics
Academic / Research Institutes
Ambulatory Surgical Centers
About us
Phase 3,Navale IT Zone, S.No. 51/2A/2,
Office No. 202, 2nd floor,
Near, Navale Brg,Narhe,
Pune, Maharashtra 411041
[email protected]Pulmonary Edema Market Size To Grow At A CAGR Of 7.8 % In The Forecast Period Of 2025-2032
Pulmonary Edema Market
Market Estimation & Definition
Pulmonary edema is a serious medical condition in which excess fluid accumulates in the lungs, impairing gas exchange and causing difficulty in breathing. It can be cardiogenic, due to heart failure, or non-cardiogenic, arising from lung injury, infection, trauma, or toxic exposure. According to Stellar Market Research, the global pulmonary edema market was valued at approximately USD 6.6 billion in 2024 and is forecast to grow at a CAGR of 7.8% from 2025 to 2032, reaching nearly USD 12.04 billion by 2032.
Request Free Sample Report:https://www.stellarmr.com/report/req_sample/pulmonary-edema-market/2673
Market Growth Drivers & Opportunity
Key factors driving the growth of the pulmonary edema market include:
Rising Cardiovascular Disease (CVD) Prevalence: Heart disease is one of the primary causes of cardiogenic pulmonary edema. With increasing global rates of heart failure, coronary artery disease and hypertension, more patients are at risk.
Growing Incidence of Trauma and Accidents: Road accidents and chest injuries contribute significantly to non-cardiogenic pulmonary edema, creating acute treatment demand.
Aging Population: As the population ages, comorbid conditions (heart disease, kidney issues) that predispose individuals to pulmonary edema become more common.
Innovative Therapies: Advances in drugs — for example, combinations such as sacubitril/valsartan — and novel therapeutics (e.g., synthetic peptides) are improving outcomes.
Improved Diagnostics: Enhanced diagnostic tools, including imaging (CT, ultrasound) and deep-learning–assisted lung evaluation, are helping earlier detection and management.
These drivers create strong opportunities for pharmaceutical companies, medical technology firms, and healthcare providers to invest in treatments, diagnostics, and long-term care solutions for pulmonary edema.
What Lies Ahead: Emerging Trends Shaping the Future
Several emerging trends are expected to shape the pulmonary edema market in the coming years:
Precision Therapies & Peptide-Based Drugs: Newer molecules like synthetic peptides (such as solnatide) are being developed to more precisely manage fluid accumulation in the lungs.
Repurposing Existing Drugs: Drugs currently used for heart failure (e.g., sacubitril/valsartan) are being more widely adopted or optimized to prevent or manage pulmonary edema.
Growth in Diagnostic Imaging: Lung ultrasound combined with AI and deep learning is emerging as a powerful tool in assessing and monitoring pulmonary edema severity.
Expansion of Healthcare Infrastructure: In emerging markets, expanding hospital capacity, better access to intensive care, and growing awareness will drive demand for pulmonary edema treatment.
Regenerative and Device-Based Support: As treatment paradigms evolve, there may be more integration of device-based support (ventilation) with pharmacological therapy.
Risks remain, including regulatory hurdles for new drugs, high costs for R&D, and inequalities in access to advanced diagnostics.
Segmentation Analysis
The report breaks down the pulmonary edema market as follows:
By Disease Type:
Cardiogenic Pulmonary Edema (driven primarily by heart failure)
Non-Cardiogenic Pulmonary Edema (caused by lung injury, infection, trauma, or altitude)
By Diagnosis Type:
Imaging Techniques (chest X-ray, CT scans, lung ultrasound)
Laboratory Tests (blood gas analysis, biomarkers)
By Treatment Type:
Oxygen Therapy (supplemental oxygen)
Medications (diuretics, vasodilators, heart failure drugs)
Surgical Interventions (e.g., valve repair, bypass grafting)
By End User:
Hospitals & Clinics
Academic / Research Institutes
Ambulatory Surgical Centers
About us
Phase 3,Navale IT Zone, S.No. 51/2A/2,
Office No. 202, 2nd floor,
Near, Navale Brg,Narhe,
Pune, Maharashtra 411041
[email protected]
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
